AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2527274
Drug: rHBV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHBV vaccine (20 micrograms)
Trial: 2527274
Drug: plasma-derived hepatitis
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plasma-derived hepatitis B virus vaccine (Hevac B Pasteur)
Trial: 2527274
Drug: rHBV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHBV vaccine (10 and 20 micrograms)
Trial: 2527274
Drug: rHBV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHBV vaccine
Trial: 1106927
Drug: Transfer factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer factor therapy (equivalent to 2‐1 X 10(8) leucocytes)
Trial: 26598475
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (RISP, LI, VAL)
Trial: 15282428
Drug: ACIST Injection
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACIST Injection System (automated contrast injection)
Trial: 15282428
Drug: Manual injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual injection (control group)
Trial: 11302274
Drug: Applied Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied Family Management (AFM) including 1 year of behavioral family therapy plus support groups for 2 years
Trial: 11302274
Drug: Supportive Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Family Management (SFM) including monthly support groups for 2 years
Trial: 11302274
Drug: Standard, low,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard, low, targeted neuroleptic dosage strategies
Trial: 11302274
Drug: Time-limited behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-limited behavioral family therapy added to monthly support groups
Trial: 9531235
Drug: Hospital-based smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-based smoking intervention consisting of a 15-minute bedside counseling session, written self-help material, a chart prompt for physicians, and up to 3 weekly counseling telephone calls after discharge.
Trial: 29735284
Drug: Music listening
RxNorm normalized name: Listerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music listening intervention (60 minutes, twice a day, over three days)
Trial: 19892350
Drug: Astaxanthin 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin 6 mg/day
Trial: 19892350
Drug: Astaxanthin 12
RxNorm normalized name: astaxanthin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin 12 mg/day
Trial: 19892350
Drug: Astaxanthin 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin 18 mg/day
Trial: 12464836
Drug: Topical aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aqueous cream
Trial: 10499484
Drug: Cholylsarcosine 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholylsarcosine 6 g/day
Trial: 10499484
Drug: Cholylsarcosine 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholylsarcosine 12 g/day
Trial: 27668927
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of daily living (Katz ADL)
Trial: 19108877
Drug: Cisplatin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (50 mg/m(2)) and Doxorubicin (45 mg/m(2))
Trial: 19108877
Drug: Cisplatin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (50 mg/m(2)), Doxorubicin (45 mg/m(2)), and Paclitaxel (160 mg/m(2))
Trial: 11824175
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of porcine secretin
Trial: 7992097
Drug: standard hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard hydroxyurea chemotherapy
Trial: 2662999
Drug: Exogenous natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous natural surfactant treatment
Trial: 2662999
Drug: Prophylactic surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic surfactant treatment at birth
Trial: 23060621
Drug: Glaucoma medications
RxNorm normalized name: ANTIGLAUCOMA MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glaucoma medications (various types including prostaglandins, β blockers, and carbonic anhydrase inhibitors)
Trial: 23060621
Drug: Glaucoma medications
RxNorm normalized name: ANTIGLAUCOMA MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glaucoma medications (various types)
Trial: 21510905
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral supplement containing vitamin A (7000 ug retinol equivalents)
Trial: 21510905
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral supplement containing beta-carotene (42 mg, or 7000 ug retinol equivalents)
Trial: 15488350
Drug: Continuous estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous estrogen and progesterone in combination (Group III)
Trial: 15488350
Drug: Cyclic estrogen
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic estrogen and progesterone combination (Group IV)
Trial: 9437560
Drug: DMPA (Depo-Provera)
RxNorm normalized name: DMPA
DrugBank: Zytron (DB11768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA (Depo-Provera) administered every 3 months
Trial: 9437560
Drug: Microgynon administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microgynon administered monthly
Trial: 26119653
Drug: Optimal Medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Medical Therapy (OMT) and revascularization
Trial: 23773733
Drug: Fasudil (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasudil (0.9 mg/dL)
Trial: 23773733
Drug: Papaverine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine (0.4 mg/mL mixed with heparinized blood)
Trial: 23773733
Drug: Histopathologic examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histopathologic examination after fasudil injection
Trial: 21118745
Drug: Generic test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic test formulation (3 tablets of 200 mg each)
Trial: 21118745
Drug: Branded reference
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded reference formulation (1 tablet of 600 mg)
Trial: 16377918
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with atorvastatin (20 mg/day) and colestimide (3 g/day)
Trial: 16377918
Drug: Intensive monotherapy
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive monotherapy with atorvastatin (40 mg/day)
Trial: 1875601
Drug: Nifedipine (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (routine drug dose tests at rest and during isometric and dynamic exercise)
Trial: 1875601
Drug: Hydrochlorothiazide (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (routine drug dose tests at rest and during isometric and dynamic exercise)
Trial: 6594492
Drug: Imipenem 10
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Imipenem 10 mg/kg
Trial: 6594492
Drug: Imipenem 25
RxNorm normalized name: imipenem 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem 25 mg/kg
Trial: 30701858
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow mesenchymal stromal cells (MSC) therapy (local and systemic administration)
Trial: 30701858
Drug: Anticytokine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticytokine therapy with infliximab (IFX)
Trial: 30701858
Drug: Antibiotic (AB)
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic (AB) and immunosuppressive (IS) therapy
Trial: 27965998
Drug: Colchicine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 1.0 mg per day for six weeks
Trial: 20194916
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (alpha‐tocopherol 400 mg/day)
Trial: 16610166
Drug: Hydroxymethylglutaryl coenzyme
RxNorm normalized name: Hydroxymethylglutaryl coenzyme A reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxymethylglutaryl coenzyme A reductase inhibitors (simvastatin) 10 mg/day plus diet (Group II)
Trial: 10438046
Drug: HBV/MF59 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV/MF59 vaccine (2 or 3 immunizations)
Trial: 10438046
Drug: HBV/MF59 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV/MF59 vaccine (2 doses, 2 months apart)
Trial: 10438046
Drug: HBV/MF59 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV/MF59 vaccine (3 injections)
Trial: 10438046
Drug: Licensed control
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licensed control vaccine (Recombivax HB)
Trial: 10438046
Drug: HBV/MF59 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV/MF59 vaccine
Trial: 7495044
Drug: Cilazapril 5
RxNorm normalized name: cilazapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 5 mg/day
Trial: 2434792
Drug: Cilazapril (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (both doses)
Trial: 380933
Drug: Neomycin ointment
RxNorm normalized name: neomycin Topical Ointment
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neomycin ointment
Trial: 31502945
Drug: internet-delivered dialectical
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-delivered dialectical behavior therapy (iDBT)
Trial: 26919405
Drug: 96-hour ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 96-hour ketamine infusion (0.6 mg/kg/h target rate) with clonidine (max 0.6 mg orally daily)
Trial: 26919405
Drug: 40-minute ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-minute ketamine infusion (0.5 mg/kg) with clonidine (max 0.6 mg orally daily)
Trial: 23232195
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (50 mg daily for 2 weeks)
Trial: 23232195
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) (200 micrograms twice daily for 10 weeks)
Trial: 23232195
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (50 mg) and MFNS
Trial: 23232195
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (50 mg)
Trial: 21491823
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg orally once daily for 6 months (Group A)
Trial: 21491823
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg vaginally once daily for 6 months (Group B)
Trial: 17363838
Drug: 3-weekly combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone or cyclophosphamide, mitoxantrone, vincristine and prednisone (CNOP) chemotherapy with or without filgrastim
Trial: 11908491
Drug: Cyclical sodium
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical sodium fluoride (NaF) 60 mg/day (6 months on, 3 months off) + calcium (1.0-1.2 g daily) + ergocalciferol (0.25 mg per 25 kg once weekly)
Trial: 11908491
Drug: No sodium
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No sodium fluoride (NaF) + calcium (1.0-1.2 g daily) + ergocalciferol (0.25 mg per 25 kg once weekly)
Trial: 30919782
Drug: Rifampin 300
RxNorm normalized name: rifampin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 300 mg/day
Trial: 25367253
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy intervention including manual therapy and exercise or electrophysiological agents and exercise
Trial: 24524874
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy intervention
Trial: 24470716
Drug: 20mg oral
RxNorm normalized name: CLOBAZAM 20MG ORAL TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg oral isotretinoin once daily for 16 weeks
Trial: 24470716
Drug: 20mg oral
RxNorm normalized name: CLOBAZAM 20MG ORAL TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg oral isotretinoin once daily along with 20% SA peels every two weeks for 16 weeks
Trial: 16116336
Drug: Statins (simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins (simvastatin or pravastatin, 10‐20 mg/d; atorvastatin, 5‐10 mg/d)
Trial: 16116336
Drug: Control (soy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (soy lecithin, 20 g/d)
Trial: 10477838
Drug: Corticosteroid withdrawal
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid withdrawal from 10 to 5 mg of prednisone (n = 21)
Trial: 10477838
Drug: Corticosteroid withdrawal
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid withdrawal from 5 to 0 mg of prednisone (n = 17)
Trial: 10477838
Drug: 14-day prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day prednisone taper in 5 patients
Trial: 7807035
Drug: Nebulized bacteriostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized bacteriostatic saline (3 mL, four times a day for 2 weeks)
Trial: 7807035
Drug: Nebulized saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized saline (placebo) (3 mL, four times a day for 2 weeks)
Trial: 7124593
Drug: Verapamil (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (0.075 and 0.15 mg/kg, not exceeding 10 mg per dose)
Trial: 30219986
Drug: Citalopram 30
RxNorm normalized name: citalopram 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 30 mg
Trial: 27777201
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of methylene blue and lidocaine plus oral valaciclovir (group A)
Trial: 27777201
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of lidocaine plus oral valaciclovir (group B)
Trial: 24161074
Drug: DASA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DASA with or without concurrent aspirin
Trial: 22742720
Drug: Alphacalcidol 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alphacalcidol 0.25 μg once daily for two weeks
Trial: 22742720
Drug: Sevelamer carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer carbonate 800 mg TID with meals for two weeks
Trial: 19548438
Drug: Shenkangbao (SKB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenkangbao (SKB) at a dose of 10 g twice a day for 3 weeks
Trial: 17611937
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (psychotherapy + pharmacotherapy)
Trial: 15109971
Drug: Operant-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operant-behavioral treatment plus cognitive coping skills training
Trial: 9655713
Drug: L-NAME 170
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME 170 mg
Trial: 7640430
Drug: C2 samples
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C2 samples taken after slowing down blood flow rate (Qb) to 100 ml per min for 3 min (C2-100)
Trial: 7640430
Drug: C2 samples
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C2 samples taken with Qb restored to 100 ml per min and the venous line clamped for 12 sec (C2-100-clamp)
Trial: 7640430
Drug: C2 samples
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C2 samples taken after slowing down blood flow rate (Qb) to 50 ml per min for 3 min (C2-50)
Trial: 7640430
Drug: C2 samples
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C2 samples taken with Qb slowed down to 50 ml per min and the venous line clamped (C2-50-clamp)
Trial: 28784673
Drug: Finafloxacin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finafloxacin (single doses of 200 to 1,000 mg)
Trial: 28784673
Drug: Finafloxacin (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finafloxacin (multiple doses of 600 to 1,000 mg)
Trial: 26269239
Drug: Pakistani almonds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pakistani almonds (10 g/d)
Trial: 26269239
Drug: American almonds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: American almonds (10 g/d)
Trial: 24037607
Drug: Perceptual learning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceptual learning treatment for the amblyopic eye
Trial: 15529479
Drug: No regular
RxNorm normalized name: Aveeno Regular Bath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No regular daily activity
Trial: 11573525
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 microg ml(‐1)
Trial: 11573525
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 microg ml(‐1)
Trial: 11573525
Drug: Propofol 4
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 4 microg ml(‐1)
Trial: 11573525
Drug: Propofol 5
RxNorm normalized name: propofol 500 MG in 50 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 5 microg ml(‐1)
Trial: 7823493
Drug: Sound vibration
RxNorm normalized name: VIBRATING DEVICE,CONSTIPATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sound vibration therapy with 2.5 kHz and 0.66 W/cm2 intensity
Trial: 15767643
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg once a day
Trial: 2841742
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin 5000 IU t.d.s.
Trial: 28625372
Drug: Subcutaneous implantable
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous implantable cardioverter defibrillator
Trial: 25965706
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg QD or 30 mg QD depending on factors)
Trial: 25965706
Drug: Enoxaparin/warfarin followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin/warfarin followed by warfarin alone
Trial: 29330461
Drug: C4 dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C4 dietary oil (10.7 g) plus 200 g carrot
Trial: 29330461
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (19 g) plus 200 g carrot
Trial: 29330461
Drug: Carrot (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrot (200 g)
Trial: 20953791
Drug: GA 20
RxNorm normalized name: Potiga 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA 20 mg/0.5 mL (reduced volume formulation)
Trial: 20953791
Drug: GA 20
RxNorm normalized name: Potiga 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA 20 mg/1.0 mL (marketed formulation)
Trial: 16947012
Drug: Ifosfamide (IFS)
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide (IFS) with three doses of mesna
Trial: 3100007
Drug: Diltiazem 120
RxNorm normalized name: diltiazem 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 120 mg
Trial: 2698566
Drug: Diltiazem 180
RxNorm normalized name: diltiazem 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 180 mg